Spencer Pharmaceutical Inc. (SPPH)
Spencer Pharmaceutical Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $29,436. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 3.69 implies it has historically moved more than the broad market.
Spencer Pharmaceutical Inc. is dedicated to pioneering drug delivery platforms aimed at addressing neurological conditions. A core aspect of their expertise lies in the precise, controlled administration of existing therapeutic compounds for central nervous system disorders, such as Alzheimer's, Parkinson's disease, and various forms of brain cancer. Moreover, the company holds a proprietary slow-release drug delivery system, which is utilized for managing type-2 diabetes and arthritis, and holds promise for other medical applications. Its operations are predominantly located in North America and Europe. Spencer Pharmaceutical Inc. was established in 1998 and maintains its headquarters in Boston, Massachusetts.
Spencer Pharmaceutical Inc. is most often compared with the following Healthcare names: